Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer

Lapatinib, targeting the human epidermal growth factor receptor family members HER1 and HER2, has been approved by the US Food and Drug Administration for use in metastatic HER2-positive breast cancer. However, resistance to lapatinib remains a common challenge to HER2-positive metastatic breast can...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Shengnan, Chen, Yi, Yang, Fan, Sun, Chunxiao, Yang, Mengzhu, Li, Wei, Huang, Xiang, Li, Jun, Wu, Hao, Yin, Yongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500445/
https://www.ncbi.nlm.nih.gov/pubmed/33013420
http://dx.doi.org/10.3389/fphar.2020.577150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500445/
https://www.ncbi.nlm.nih.gov/pubmed/33013420
http://dx.doi.org/10.3389/fphar.2020.577150

Ejemplares similares